QR Kodea

CRISPR–Cas9 Therapeutics in Early Clinical Development: Delivery and Molecular Diagnostics

CRISPR–Cas9 has progressed from an experimental tool to a therapeutic modality, marked by the first regulatory approvals of an ex vivo-edited autologous CD34+ hematopoietic stem cell product that induces fetal hemoglobin (CASGEVY/exa-cel). In this narrative review, we synthesize modality-specific mo...

Deskribapen osoa

Gorde:
Egile Nagusiak: Adrianna Rutkowska, Tadeusz Strózik, Tomasz Wasiak, Damian Ciunowicz, Natalia Kapelan, Natalia Szczepaniak, Juliusz Sosnowski, Weronika Goślińska, Jakub Bartkowiak, Agata Budny-Lewandowska, Patrycja Antończyk, Maria Markiewicz, Piotr Gustaw, Kamil Filiks, Maria Jaskólska, Ewelina Stoczyńska-Fidelus
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: MDPI AG 2026-04-01
Saila:Cells
Gaiak:
CRISPR–Cas9
genome editing
gene therapy
delivery systems
molecular diagnostics
clinical trials
Sarrera elektronikoa:https://www.mdpi.com/2073-4409/15/7/644
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak